<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39446164</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>Pentoxifylline in COVID-19 and considerations for its research in long COVID.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-024-01942-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Pentoxifylline (PTX) affects most blood components and the blood vessels, potentially modulating various conditions. Due to its impact on markers linked to COVID-19 severity, research has explored PTX for acute COVID-19. Following the widespread administration of COVID-19 vaccinations, there has been a notable and consistently growing increase in research focusing on long COVID. Consequently, our examination of relevant acute COVID-19 data shall additionally be contextualized into long COVID research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Various Databases were searched until July 2024 for all primary clinical studies on Pentoxifylline (PTX) in COVID-19.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Studies were on acute infection with SARS-CoV-2 where PTX was an adjuvant to standard therapy for ethical and practical reasons under the circumstance. PTX generally reduced hospitalization duration and improved some inflammatory markers, but its impact on mortality was inconsistent. Adverse events were minimal. Meta-analysis revealed a significant reduction in hospitalization duration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This systematic review and meta-analysis suggest that adding pentoxifylline (PTX) to standard COVID-19 therapy may significantly reduce hospitalization duration and improve some inflammatory markers. However, its impact on mortality rates is inconclusive. Adverse events are minimal. PTX can be favorable as an add-on in managing acute COVID-19 and could reduce the risk of long COVID, as well as assist in managing many of its most common symptoms.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramzi</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-1737-8235</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maya</LastName><ForeName>Subhia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0649-7049</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Damascus University, Damascus, Syria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balousha</LastName><ForeName>Nadeen</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4210-3089</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Mufreh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-8882-5116</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiha</LastName><ForeName>Mostafa Ramzi</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0009-0001-4785-2273</Identifier><AffiliationInfo><Affiliation>Faculty of Urban and Regional Planning, Cairo University, Giza, Egypt. Ramzy_220202@stud.furp.cu.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Meta-Analysis</Keyword><Keyword MajorTopicYN="N">Pentoxifylline</Keyword><Keyword MajorTopicYN="N">Systematic Review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39446164</ArticleId><ArticleId IdType="doi">10.1007/s00011-024-01942-0</ArticleId><ArticleId IdType="pii">10.1007/s00011-024-01942-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol. 1994;30(4):603&#x2013;21. https://doi.org/10.1016/S0190-9622(94)70069-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0190-9622(94)70069-9</ArticleId><ArticleId IdType="pubmed">8157787</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton JE, Brogden RN. Pentoxifylline (Oxpentifylline). Drugs Aging. 1995;7(6):480&#x2013;503. https://doi.org/10.2165/00002512-199507060-00007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002512-199507060-00007</ArticleId><ArticleId IdType="pubmed">8601054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, et al. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol. 2004;9(2):103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19641695</ArticleId><ArticleId IdType="pmc">2716262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34(1):50&#x2013;97. https://doi.org/10.2165/00003495-198734010-00003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-198734010-00003</ArticleId><ArticleId IdType="pubmed">3308412</ArticleId></ArticleIdList></Reference><Reference><Citation>Effendi WI, et al. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9(3):785. https://doi.org/10.3390/cells9030785 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9030785</ArticleId><ArticleId IdType="pubmed">32213945</ArticleId><ArticleId IdType="pmc">7140859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen KH, et al. Comparative bioavailability study of two controlled-release pentoxifylline tablet preparations. Drug Dev Ind Pharm. 2000;26(7):803&#x2013;7. https://doi.org/10.1081/DDC-100101303 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/DDC-100101303</ArticleId><ArticleId IdType="pubmed">10872103</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication mechanism of action pharmacokinetics clinical efficacy and adverse effects. Pharmacotherapy The J Human Pharmacol Drug Therapy. 1984;4(6):297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1875-9114.1984.tb03380.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques LJ, et al. Pentoxifylline inhibits TNF-&#x3b1; production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508&#x2013;11. https://doi.org/10.1164/ajrccm.159.2.9804085 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.159.2.9804085</ArticleId><ArticleId IdType="pubmed">9927365</ArticleId></ArticleIdList></Reference><Reference><Citation>Brie D, et al. Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2016;34(12):2318&#x2013;29. https://doi.org/10.1097/HJH.0000000000001086 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001086</ArticleId><ArticleId IdType="pubmed">27512972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasyid A, et al. Pentoxifylline in acute ischemic stroke patients with blood hyperviscosity. Int J Appl Pharma. 2018;10(1):307&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.22159/ijap.2018.v10s1.68</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Furth A, et al. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-&#x3b1;, IL-1&#x3b2; and IL-10 by human leucocytes. Immunology. 1997;91(2):193&#x2013;6. https://doi.org/10.1046/j.1365-2567.1997.00252.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.1997.00252.x</ArticleId><ArticleId IdType="pubmed">9227316</ArticleId><ArticleId IdType="pmc">1363846</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekhuizen M, et al. Pentoxifylline as a therapeutic option for pre-eclampsia: a study on its placental effects. Br J Pharmacol. 2022;179(22):5074&#x2013;88. https://doi.org/10.1111/bph.15931 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15931</ArticleId><ArticleId IdType="pubmed">35861684</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyit M, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med. 2021;40:110&#x2013;4. https://doi.org/10.1016/j.ajem.2020.11.058 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.11.058</ArticleId><ArticleId IdType="pubmed">33309506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong X, et al. Thrombocytopenia is associated with COVID-19 severity and outcome: an updated meta-analysis of 5637 patients with multiple outcomes. Laboratory Med. 2021;52(1):10&#x2013;5. https://doi.org/10.1093/labmed/lmaa067 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/labmed/lmaa067</ArticleId></ArticleIdList></Reference><Reference><Citation>Izcovich A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS ONE. 2020;15(11):E0241955. https://doi.org/10.1371/journal.pone.0241955 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241955</ArticleId><ArticleId IdType="pubmed">33201896</ArticleId><ArticleId IdType="pmc">7671522</ArticleId></ArticleIdList></Reference><Reference><Citation>Violetis OA, et al. COVID-19 infection and haematological involvement: a review of epidemiology, pathophysiology and prognosis of full blood count findings. SN Comprehensive Clinical Med. 2020;2(8):1089&#x2013;93. https://doi.org/10.1007/s42399-020-00380-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00380-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulkoti VS, et al. Association of serum ferritin with COVID-19 in a cross-sectional study of 200 intensive care unit patients in a rural hospital: Is ferritin the forgotten biomarker of mortality in severe COVID-19? J Family Med Primary Care. 2022;11(5):2045&#x2013;50. https://doi.org/10.4103/jfmpc.jfmpc_1921_21 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1921_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurian SJ, et al. Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facility. Clinical Epidemiol Global Health. 2023;21: 101295. https://doi.org/10.1016/j.cegh.2023.101295 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cegh.2023.101295</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado V, Loza-Mejia MA, Chavez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Med Hypotheses. 2020;144: 109988. https://doi.org/10.1016/j.mehy.2020.109988 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109988</ArticleId><ArticleId IdType="pubmed">32540603</ArticleId><ArticleId IdType="pmc">7282759</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Choi SH, Cho YD, Kim JY, Cho HJ, Kim KH, et al. Protective effects of pentoxifylline on T-cell viability under inflammatory conditions. Eur J Inflamm. 2022;20:1&#x2013;10. https://doi.org/10.1177/1721727X221120 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1721727X221120</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Hellencourt CL, et al. Differential regulation of TNF&#x3b1;, IL-1&#x3b2;, IL-6, IL-8, TNF&#x3b2;, and IL-10 by pentoxifylline. Int J Immunopharmacol. 1996;18(12):739&#x2013;48. https://doi.org/10.1016/S0192-0561(97)85556-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0192-0561(97)85556-7</ArticleId><ArticleId IdType="pubmed">9172017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z, et al. Visual analysis of hotspots and trends in long COVID research based on bibliometric. Heliyon. 2024;10(2): e24053. https://doi.org/10.1016/j.heliyon.2024.e24053 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e24053</ArticleId><ArticleId IdType="pubmed">38293444</ArticleId><ArticleId IdType="pmc">10827472</ArticleId></ArticleIdList></Reference><Reference><Citation>Azizi H, et al. Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial. Int Immunopharmacol. 2021;101(Pt B): 108227. https://doi.org/10.1016/j.intimp.2021.108227 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108227</ArticleId><ArticleId IdType="pubmed">34666302</ArticleId><ArticleId IdType="pmc">8492603</ArticleId></ArticleIdList></Reference><Reference><Citation>Eghbali A, et al. Evaluation of Pentoxifylline and Colchicine administration on clinical outcomes of hospitalized patients with COVID-19. J Babol Univ Med Sci. 2023;25(1):497&#x2013;508.</Citation></Reference><Reference><Citation>Maldonado V, et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. Int Immunopharmacol. 2021;90: 107209. https://doi.org/10.1016/j.intimp.2020.107209 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107209</ArticleId><ArticleId IdType="pubmed">33278747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarhan RM, et al. Pentoxifylline effects on hospitalized COVID-19 patients with cytokine storm syndrome: a randomized clinical trial. Pharmaceuticals. 2023;16(4):631. https://doi.org/10.3390/ph16040631 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040631</ArticleId><ArticleId IdType="pubmed">37111389</ArticleId><ArticleId IdType="pmc">10142327</ArticleId></ArticleIdList></Reference><Reference><Citation>Seirafianpour, F., et al., (2023). Efficacy and Safety of Oral Pentoxifylline in the Treatment and Recovery of Patients with Moderate to Severe COVID-19 Infection Treated with Routine Protocols: A Randomized Controlled Clinical Trial. Authorea Preprints https://doi.org/10.22541/au.168440425.54575375/v1</Citation></Reference><Reference><Citation>Chavarr&#xed;a AP, et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput Struct Biotechnol J. 2021;19:1379&#x2013;90. https://doi.org/10.1016/j.csbj.2021.02.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.02.009</ArticleId><ArticleId IdType="pubmed">33680348</ArticleId><ArticleId IdType="pmc">7910139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Lu&#xe9;vano M, et al. Pilot study: management with pentoxifylline in patients with chronic liver disease and COVID-19. Ann Hepatol. 2022;27: 100838. https://doi.org/10.1016/j.aohep.2022.100838 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aohep.2022.100838</ArticleId><ArticleId IdType="pmc">9713531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall GC, et al. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support. Clin Respir J. 2021;15(7):843&#x2013;6. https://doi.org/10.1111/crj.13363 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.13363</ArticleId><ArticleId IdType="pubmed">33735520</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;ora AR, Celik E, Karadem KB. Aortic thrombosis in the course of Covid-19 disease; two rare cases. Annals Vascular Surg. 2021;73:118.e1-118.e3. https://doi.org/10.1016/j.avsg.2021.02.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2021.02.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekara S, et al. Post COVID inflammation syndrome: different manifestations caused by the virus. J Assoc Physicians India. 2020;68(12):33&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33247640</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisa M, et al. SARS-COV-2 infection in patients with alcohol associated hepatitis: Challenge of treatment options: metabolic similarities and treatment challenges. Am J Gastroenterol. 2020;116(4):847&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001002</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa G, et al. COVID-19 and Beh&#xe7;et&#x2019;s disease: clinical case series. Ann Rheum Dis. 2021;80(3):E41-e41. https://doi.org/10.1136/annrheumdis-2020-217778 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217778</ArticleId><ArticleId IdType="pubmed">32719040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneria MV, Nadaf S, Desai U. Clots in COVID: A case series. Indian J Critical Care Med. 2021;25(7):817&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10071-23897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kler R, Vaishnav D, Banerjee MP, et al. Combination therapy with Azithromycin, Pentoxifylline and Dexamethasone shows Complete Recovery in Severe COVID 19: Case Series of Patients in First and Second wave of Pandemic in India. 2021. https://doi.org/10.21203/rs.3.rs-762889/v1</Citation></Reference><Reference><Citation>Malinowski K, et al. Transient spontaneous osteonecrosis of the knee (SONK) shortly after SARS-CoV-2 infection: A report of 2 cases. Adv Clin Exp Med. 2022;31(9):1035&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/153004</ArticleId><ArticleId IdType="pubmed">36135812</ArticleId></ArticleIdList></Reference><Reference><Citation>Modrzejewska M, Cyrankiewicz J, Zdanowska O, Bosy-G&#x105;sior W. Isolated depo-medrol administration under tenon&#x2019;s capsule for post-COVID-19 uveitis in a child: a case report and literature review. J Clin Med. 2024;13(5):1341. https://doi.org/10.3390/jcm13051341 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13051341</ArticleId><ArticleId IdType="pubmed">38592169</ArticleId><ArticleId IdType="pmc">10932394</ArticleId></ArticleIdList></Reference><Reference><Citation>Surya SP, Santoso RM. A clinical case series of COVID-19-associated acute limb ischemia: real-world situation. The Egyptian Heart J. 2021;73(1):59. https://doi.org/10.1186/s43044-021-00187-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43044-021-00187-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira JG, et al. Diagnosis and management of patients with acute limb ischemia after Covid-19 infection: a case series. J Vascular Brasileiro. 2022;21:E20220044. https://doi.org/10.1590/1677-5449.202200442 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1677-5449.202200442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni, M., Personalized Expanded Kelleni&#x2019;s Immunomodulatory COVID-19 Protocol Safely Used to Manage Severe COVID-22: A Case-Report. 2022. https://doi.org/10.31219/osf.io/ysfr2</Citation></Reference><Reference><Citation>Nassani N, et al. Leukocytoclastic vasculitis in cutaneous crohn disease in the setting of COVID-19. Inflamm Bowel Dis. 2021;27(6):E74-e75. https://doi.org/10.1093/ibd/izab045 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab045</ArticleId><ArticleId IdType="pubmed">33616186</ArticleId></ArticleIdList></Reference><Reference><Citation>Topel &#xc7;, et al. Aortic floating thrombi with lower limb ischemia and renal infarct in COVID-19: A remote thromboembolic complication. Turk Kardiyoloji Dernegi Arsivi. 2021;49(3):233. https://doi.org/10.5543/tkda.2021.12901 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5543/tkda.2021.12901</ArticleId><ArticleId IdType="pubmed">33847272</ArticleId></ArticleIdList></Reference><Reference><Citation>Toker M, et al. COVID&#x2013;19-associated diffuse dermal angiomatosis managed with pentoxifylline and topical timolol. J Am Academy Dermatol Case Rep. 2023;39:34&#x2013;6.</Citation></Reference><Reference><Citation>de Oliveira Valentim F, Tsutsui GM, Miot HA. Recrudescence of livedoid vasculopathy induced by COVID-19. Int J Dermatol. 2021;60(5):E185.</Citation></Reference><Reference><Citation>Weltman E, Kotecha R. Early-onset symptomatic radiation necrosis after stereotactic radiosurgery in the setting of COVID-19 infection. Med Dosim. 2021;46(4):374&#x2013;6. https://doi.org/10.1016/j.meddos.2021.04.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meddos.2021.04.002</ArticleId><ArticleId IdType="pubmed">33910768</ArticleId><ArticleId IdType="pmc">8041142</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice. Antiviral Chem Chemother. 2006;17(5):275&#x2013;84. https://doi.org/10.1177/095632020601700505 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632020601700505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo Martin JF, Jim&#xe9;nez JL, Mu&#xf1;oz-Fern&#xe1;ndez A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med Sci Monitor. 2003;9(6):Sr29-34.</Citation></Reference><Reference><Citation>Gheorghita R, et al. The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches. Front Immunol. 2024;15:1344086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1344086</ArticleId><ArticleId IdType="pubmed">38500880</ArticleId><ArticleId IdType="pmc">10944866</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao T, et al. Research progress of post-acute sequelae after SARS-CoV-2 infection. Cell Death Dis. 2024;15(4):257. https://doi.org/10.1038/s41419-024-06642-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-024-06642-5</ArticleId><ArticleId IdType="pubmed">38605011</ArticleId><ArticleId IdType="pmc">11009241</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, et al. A systematic review and meta-analysis of long COVID symptoms. Syst Rev. 2023;12(1):88. https://doi.org/10.1186/s13643-023-02250-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02250-0</ArticleId><ArticleId IdType="pubmed">37245047</ArticleId><ArticleId IdType="pmc">10220332</ArticleId></ArticleIdList></Reference><Reference><Citation>Farajollahi-Moghadam M, et al. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol. 2021;36(3):140&#x2013;6. https://doi.org/10.1097/yic.0000000000000353 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/yic.0000000000000353</ArticleId><ArticleId IdType="pubmed">33724254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad TAM, et al. Pentoxifylline as a novel add-on therapy for major depressive disorder in adult patients: a randomized, double-blind. Placebo-Controlled Trial Pharmacopsychiatry. 2024. https://doi.org/10.1055/a-2291-7204 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-2291-7204</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Haggar SM, Eissa MA, Mostafa TM, El-Attar KS, Abdallah MS. The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Psychother Psychosom. 2018;87(6):331&#x2013;9. https://doi.org/10.1159/000492619 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492619</ArticleId><ArticleId IdType="pubmed">30205379</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasrebi SO, Momtazmanesh S, Moghaddam HS, Shahmansouri N, Mehrpooya M, Arbabi M, Ghazizadeh-Hashemi F, Akhondzadeh S. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial. J Psychosom Res. 2021;150: 110635. https://doi.org/10.1016/j.jpsychores.2021.110635 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2021.110635</ArticleId><ArticleId IdType="pubmed">34627009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AG, et al. An open-label randomized study to evaluate the safety and efficacy of ciprofloxacin compared to ampicillin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother. 1996;37(3):557&#x2013;64.</Citation></Reference><Reference><Citation>Akhondzadeh S, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:32&#x2013;6. https://doi.org/10.1016/j.pnpbp.2009.09.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2009.09.012</ArticleId><ArticleId IdType="pubmed">19772883</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinichi F, et al. Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial. J Psychopharmacol. 2023;37(10):1003&#x2013;10. https://doi.org/10.1177/02698811231186760 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02698811231186760</ArticleId><ArticleId IdType="pubmed">37466276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlov P, et al. Diagnostics and treatment of non-alcoholic steatohepatitis: A clinical guide. Hep Intl. 2021;15(5):1001&#x2013;15.</Citation></Reference><Reference><Citation>Parnetti L, et al. Relationship between haemorrheological factors and initial mental deterioration in the elderly: A preliminary study. Clinical Hemorheol. 1985;5:361&#x2013;72.</Citation></Reference><Reference><Citation>Seb&#x151;k S, Gyires K. Long COVID and possible preventive options. Inflammopharmacol. 2023;31(6):2807&#x2013;17. https://doi.org/10.1007/s10787-023-01204-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01204-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med. 2021;92:55&#x2013;70. https://doi.org/10.1016/j.ejim.2021.06.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId><ArticleId IdType="pmc">8206636</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo De, Mei B, Wang P, Kuang F, Li B, Su S. Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(3):328&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.10.016</ArticleId><ArticleId IdType="pubmed">37866679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>